Concepts (132)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Circulating Tumor DNA | 5 | 2024 | 48 | 2.920 |
Why?
|
| Appendiceal Neoplasms | 9 | 2024 | 31 | 2.530 |
Why?
|
| Colorectal Neoplasms | 11 | 2024 | 979 | 2.170 |
Why?
|
| Peritoneal Neoplasms | 11 | 2024 | 181 | 2.110 |
Why?
|
| Hyperthermia, Induced | 8 | 2024 | 73 | 1.600 |
Why?
|
| Colonic Neoplasms | 5 | 2024 | 571 | 1.250 |
Why?
|
| Rectal Neoplasms | 5 | 2024 | 129 | 1.030 |
Why?
|
| Neoplasm Recurrence, Local | 5 | 2024 | 1350 | 0.820 |
Why?
|
| Adenocarcinoma | 7 | 2024 | 1183 | 0.700 |
Why?
|
| Precision Medicine | 1 | 2024 | 413 | 0.670 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 14 | 2024 | 2505 | 0.660 |
Why?
|
| Biomarkers, Tumor | 3 | 2024 | 1542 | 0.650 |
Why?
|
| Cytoreduction Surgical Procedures | 11 | 2024 | 79 | 0.550 |
Why?
|
| Fluorouracil | 3 | 2024 | 549 | 0.460 |
Why?
|
| Pancreatic Neoplasms | 3 | 2024 | 684 | 0.440 |
Why?
|
| Neoplasm Staging | 4 | 2024 | 2000 | 0.370 |
Why?
|
| Radiosurgery | 2 | 2024 | 287 | 0.350 |
Why?
|
| Humans | 34 | 2024 | 89864 | 0.330 |
Why?
|
| Liver Neoplasms | 3 | 2024 | 755 | 0.320 |
Why?
|
| Microsatellite Instability | 3 | 2024 | 53 | 0.310 |
Why?
|
| Mutation | 6 | 2024 | 4164 | 0.290 |
Why?
|
| Retrospective Studies | 12 | 2024 | 9185 | 0.290 |
Why?
|
| Aged, 80 and over | 5 | 2024 | 6779 | 0.290 |
Why?
|
| Celecoxib | 2 | 2024 | 31 | 0.280 |
Why?
|
| Combined Modality Therapy | 7 | 2024 | 1704 | 0.280 |
Why?
|
| Male | 16 | 2024 | 42614 | 0.280 |
Why?
|
| Female | 17 | 2024 | 46529 | 0.280 |
Why?
|
| Neoadjuvant Therapy | 3 | 2024 | 376 | 0.270 |
Why?
|
| Middle Aged | 13 | 2024 | 26103 | 0.270 |
Why?
|
| Survival Rate | 7 | 2023 | 1898 | 0.270 |
Why?
|
| Pyridines | 2 | 2024 | 300 | 0.250 |
Why?
|
| Adult | 12 | 2024 | 26784 | 0.250 |
Why?
|
| Aged | 9 | 2024 | 19230 | 0.250 |
Why?
|
| MutS Homolog 2 Protein | 1 | 2024 | 33 | 0.240 |
Why?
|
| Cyclooxygenase 2 Inhibitors | 1 | 2024 | 33 | 0.230 |
Why?
|
| Anilides | 1 | 2024 | 45 | 0.230 |
Why?
|
| Class I Phosphatidylinositol 3-Kinases | 1 | 2024 | 64 | 0.230 |
Why?
|
| Phenylurea Compounds | 1 | 2024 | 95 | 0.220 |
Why?
|
| Quinolines | 1 | 2024 | 86 | 0.220 |
Why?
|
| Peritoneum | 4 | 2024 | 57 | 0.220 |
Why?
|
| Surgical Oncology | 1 | 2023 | 28 | 0.220 |
Why?
|
| Mutation, Missense | 1 | 2024 | 280 | 0.210 |
Why?
|
| Appendix | 1 | 2023 | 31 | 0.210 |
Why?
|
| Vaccines | 1 | 2024 | 84 | 0.210 |
Why?
|
| Cancer Vaccines | 1 | 2024 | 159 | 0.210 |
Why?
|
| Quality Assurance, Health Care | 1 | 2024 | 225 | 0.200 |
Why?
|
| Neuroendocrine Tumors | 1 | 2024 | 124 | 0.200 |
Why?
|
| C-Reactive Protein | 1 | 2023 | 191 | 0.200 |
Why?
|
| Molecular Targeted Therapy | 1 | 2024 | 279 | 0.200 |
Why?
|
| Antineoplastic Agents | 2 | 2024 | 2328 | 0.200 |
Why?
|
| Germ-Line Mutation | 1 | 2024 | 347 | 0.200 |
Why?
|
| Ataxia Telangiectasia Mutated Proteins | 1 | 2021 | 57 | 0.190 |
Why?
|
| Palliative Care | 1 | 2023 | 264 | 0.190 |
Why?
|
| DNA Breaks, Double-Stranded | 1 | 2021 | 67 | 0.190 |
Why?
|
| Protein Kinase Inhibitors | 2 | 2024 | 586 | 0.190 |
Why?
|
| Disease-Free Survival | 4 | 2024 | 1168 | 0.180 |
Why?
|
| Tumor Microenvironment | 1 | 2024 | 476 | 0.180 |
Why?
|
| Lung Neoplasms | 2 | 2023 | 2368 | 0.180 |
Why?
|
| Mitoxantrone | 1 | 2020 | 67 | 0.170 |
Why?
|
| Cytarabine | 1 | 2020 | 219 | 0.170 |
Why?
|
| Etoposide | 1 | 2020 | 206 | 0.170 |
Why?
|
| Leucovorin | 3 | 2024 | 222 | 0.170 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2024 | 952 | 0.150 |
Why?
|
| Neoplasms | 2 | 2024 | 3062 | 0.140 |
Why?
|
| Head and Neck Neoplasms | 1 | 2021 | 1061 | 0.120 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2023 | 1130 | 0.120 |
Why?
|
| Myeloproliferative Disorders | 1 | 2016 | 133 | 0.110 |
Why?
|
| Leukemia, Myeloid, Acute | 1 | 2020 | 798 | 0.110 |
Why?
|
| Chemotherapy, Cancer, Regional Perfusion | 2 | 2023 | 18 | 0.110 |
Why?
|
| Carcinoembryonic Antigen | 2 | 2023 | 40 | 0.100 |
Why?
|
| Chemotherapy, Adjuvant | 2 | 2024 | 476 | 0.100 |
Why?
|
| Prospective Studies | 3 | 2024 | 4322 | 0.090 |
Why?
|
| Double-Blind Method | 2 | 2024 | 1714 | 0.080 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2024 | 854 | 0.080 |
Why?
|
| Recurrence | 2 | 2023 | 1144 | 0.080 |
Why?
|
| Immunotherapy | 2 | 2024 | 693 | 0.070 |
Why?
|
| Cohort Studies | 2 | 2023 | 2886 | 0.070 |
Why?
|
| Quality of Life | 2 | 2024 | 1680 | 0.060 |
Why?
|
| DNA Mismatch Repair | 1 | 2024 | 58 | 0.060 |
Why?
|
| Colorectal Neoplasms, Hereditary Nonpolyposis | 1 | 2024 | 47 | 0.060 |
Why?
|
| Organoplatinum Compounds | 1 | 2024 | 94 | 0.060 |
Why?
|
| Capecitabine | 1 | 2024 | 93 | 0.060 |
Why?
|
| Standard of Care | 1 | 2024 | 65 | 0.060 |
Why?
|
| Trifluridine | 1 | 2023 | 6 | 0.060 |
Why?
|
| Advance Directives | 1 | 2023 | 64 | 0.050 |
Why?
|
| Organ Sparing Treatments | 1 | 2023 | 46 | 0.050 |
Why?
|
| Preoperative Period | 1 | 2023 | 94 | 0.050 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 1 | 2024 | 165 | 0.050 |
Why?
|
| Neoplasm Grading | 1 | 2024 | 374 | 0.050 |
Why?
|
| Radiotherapy Planning, Computer-Assisted | 1 | 2024 | 185 | 0.050 |
Why?
|
| HLA Antigens | 1 | 2024 | 227 | 0.050 |
Why?
|
| Carcinoma, Pancreatic Ductal | 1 | 2024 | 120 | 0.050 |
Why?
|
| Anal Canal | 1 | 2023 | 88 | 0.050 |
Why?
|
| Liquid Biopsy | 1 | 2022 | 36 | 0.050 |
Why?
|
| Monoterpenes | 1 | 2022 | 5 | 0.050 |
Why?
|
| GPI-Linked Proteins | 1 | 2022 | 51 | 0.050 |
Why?
|
| Antigens, Neoplasm | 1 | 2024 | 334 | 0.050 |
Why?
|
| Tumor Suppressor p53-Binding Protein 1 | 1 | 2021 | 12 | 0.050 |
Why?
|
| G2 Phase Cell Cycle Checkpoints | 1 | 2021 | 12 | 0.050 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2023 | 268 | 0.050 |
Why?
|
| Interleukin-6 | 1 | 2023 | 261 | 0.050 |
Why?
|
| Drug Combinations | 1 | 2022 | 203 | 0.050 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2023 | 405 | 0.050 |
Why?
|
| Preoperative Care | 1 | 2023 | 395 | 0.050 |
Why?
|
| Chemoradiotherapy | 1 | 2023 | 306 | 0.050 |
Why?
|
| Immunologic Factors | 1 | 2022 | 171 | 0.050 |
Why?
|
| Treatment Outcome | 2 | 2024 | 8264 | 0.040 |
Why?
|
| Tumor Burden | 1 | 2021 | 310 | 0.040 |
Why?
|
| Administration, Oral | 1 | 2022 | 666 | 0.040 |
Why?
|
| Postoperative Period | 1 | 2021 | 301 | 0.040 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2023 | 412 | 0.040 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2021 | 484 | 0.040 |
Why?
|
| Mice, Nude | 1 | 2021 | 816 | 0.040 |
Why?
|
| Prevalence | 1 | 2023 | 1250 | 0.040 |
Why?
|
| Chronic Disease | 1 | 2023 | 958 | 0.040 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2023 | 490 | 0.040 |
Why?
|
| Biopsy | 1 | 2023 | 1184 | 0.040 |
Why?
|
| Cell Cycle Proteins | 1 | 2021 | 399 | 0.040 |
Why?
|
| Disease Progression | 1 | 2023 | 1469 | 0.040 |
Why?
|
| Length of Stay | 1 | 2021 | 745 | 0.040 |
Why?
|
| Inflammation | 1 | 2023 | 981 | 0.040 |
Why?
|
| Biomarkers | 1 | 2023 | 1774 | 0.030 |
Why?
|
| Cell Line, Tumor | 1 | 2021 | 2583 | 0.030 |
Why?
|
| Cell Proliferation | 1 | 2021 | 1669 | 0.030 |
Why?
|
| Apoptosis | 1 | 2021 | 1717 | 0.030 |
Why?
|
| Prognosis | 1 | 2023 | 3789 | 0.030 |
Why?
|
| Illinois | 1 | 2016 | 485 | 0.030 |
Why?
|
| Signal Transduction | 1 | 2021 | 3403 | 0.020 |
Why?
|
| Postoperative Complications | 1 | 2021 | 2301 | 0.020 |
Why?
|
| Young Adult | 1 | 2020 | 6389 | 0.020 |
Why?
|
| Mice | 1 | 2021 | 11846 | 0.020 |
Why?
|
| Animals | 1 | 2021 | 27516 | 0.010 |
Why?
|